Immunologic evidence of a strong association between non-Hodgkin lymphoma and simian virus 40.

BACKGROUNDNon-Hodgkin lymphoma (NHL), the most common cancer of the lymphatic system, is of unknown etiology. The identification of etiologic factors in the onset of NHL is a key event that could facilitate the prevention and cure of this malignancy. Simian virus 40 (SV40) has been considered an oncogenic agent in the onset/progression of NHL. METHODSIn this study, an indirect enzyme-linked immunosorbent assay with 2 synthetic peptides that mimic SV40 antigens of viral capsid proteins 1 to 3 was employed to detect specific antibodies against SV40. Serum samples were taken from 2 distinct cohorts of NHL-affected patients (NHL1 [n=89] and NHL2 [n=61]) along with controls represented by oncologic patients affected by breast cancer (BC; n=78) and undifferentiated nasopharyngeal carcinoma (UNPC; n=64) and 3 different cohorts of healthy subjects (HSs; HS1 [n=130], HS2 [n=83], and HS3 [n=87]). RESULTSImmunologic data indicated that in serum samples from NHL patients, antibodies against SV40 mimotopes were detectable with a prevalence of 40% in NHL1 patients and with a prevalence of 43% in NHL2 patients. In HSs of the same median age as NHL patients, the prevalence was 16% for the HS1 group (57 years) and 14% for the HS2 group (65 years). The difference was statistically significant (P<.0001 and P<.001). Interestingly, the difference between NHL1/NHL2 patients and BC patients (40%/43% vs 15%, P<.001) and between NHL1/NHL2 patients and UNPC patients (40%/43% vs 25%, P<.05) was significant. CONCLUSIONSOur data indicate a strong association between NHL and SV40 and thus a need for innovative therapeutic approaches for this hematologic malignancy. Cancer 2015;121:2618-2626. (c) 2015 American Cancer Society. Non-Hodgkin lymphoma, the most common cancer of the lymphatic system, is of unknown etiology. The data indicate a strong association between non-Hodgkin lymphoma and simian virus 40 and thus suggest the need for innovative therapeutic approaches for this hematologic malignancy.